Half-Year Review of Inventiva’s Liquidity Contract with Kepler
Cheuvreux
Daix (France),
Long Island City (New York, United States), January 24,
2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the
“Company”), a clinical-stage biopharmaceutical company focused on
the development of oral small molecule therapies for the treatment
of patients with non-alcoholic steatohepatitis (“NASH”) and other
diseases with significant unmet medical needs, today announced the
half-year report of its liquidity contract with Kepler
Cheuvreux.Under the liquidity contract granted to Kepler Cheuvreux
by Inventiva, the following resources were available in the
liquidity account as of December 31, 2023:
- Cash: € 416,331.34
- Number of shares: 83,228
- Number of executions on buy side on
semester: 828
- Number of executions on sell side
on semester: 877
- Traded volume on buy side on semester: 157,508 shares for €
584,045.97
- Traded volume on sell side on
semester: 180,395 shares for € 695,421.23
At the last half-year report as of June 30,
2023, the following resources were available in the liquidity
account:
- Cash: € 299,865.86
- Number of shares: 106,115
- Number of executions on buy side on
semester: 1,023
- Number of executions on sell side
on semester: 1,071
- Traded volume on buy side on semester: 214,181 shares for €
823,005.84
- Traded volume on sell side on
semester: 221,069 shares for € 839,809.73
When the contract was initially implemented, the
following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
|
Buy Side |
|
Sell Side |
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
Total |
828 |
157 508 |
584 045,97 |
|
877 |
180 395 |
695 421,23 |
07/03/2023 |
- |
- |
- |
|
6 |
750 |
2 827,50 |
07/04/2023 |
4 |
750 |
2 782,50 |
|
2 |
750 |
2 827,50 |
07/05/2023 |
8 |
1 750 |
6 545,00 |
|
4 |
287 |
1 107,82 |
07/06/2023 |
12 |
2 500 |
9 000,00 |
|
1 |
1 |
3,76 |
07/07/2023 |
2 |
750 |
2 632,50 |
|
8 |
1 250 |
4 487,50 |
07/10/2023 |
- |
- |
- |
|
13 |
3 462 |
13 155,60 |
07/11/2023 |
4 |
250 |
960,00 |
|
7 |
1 250 |
4 850,00 |
07/12/2023 |
2 |
750 |
2 857,50 |
|
7 |
500 |
1 915,00 |
07/13/2023 |
4 |
250 |
947,50 |
|
3 |
1 000 |
3 800,00 |
07/14/2023 |
6 |
750 |
2 782,50 |
|
3 |
362 |
1 375,60 |
07/17/2023 |
9 |
2 250 |
8 235,00 |
|
6 |
1 039 |
3 885,86 |
07/18/2023 |
3 |
500 |
1 810,00 |
|
8 |
1 999 |
7 476,26 |
07/19/2023 |
15 |
574 |
2 158,24 |
|
3 |
450 |
1 714,50 |
07/20/2023 |
12 |
2 426 |
8 879,16 |
|
2 |
250 |
940,00 |
07/21/2023 |
5 |
1 000 |
3 620,00 |
|
6 |
748 |
2 752,64 |
07/24/2023 |
9 |
2 000 |
7 120,00 |
|
6 |
301 |
1 095,64 |
07/25/2023 |
13 |
2 913 |
9 816,81 |
|
15 |
2 100 |
7 140,00 |
07/26/2023 |
9 |
2 349 |
8 080,56 |
|
9 |
2 250 |
7 830,00 |
07/27/2023 |
4 |
1 250 |
4 475,00 |
|
17 |
4 551 |
16 565,64 |
07/28/2023 |
5 |
1 000 |
3 570,00 |
|
6 |
750 |
2 700,00 |
07/31/2023 |
- |
- |
- |
|
10 |
1 962 |
7 337,88 |
08/02/2023 |
11 |
2 500 |
9 125,00 |
|
- |
- |
- |
08/03/2023 |
1 |
500 |
1 800,00 |
|
- |
- |
- |
08/04/2023 |
3 |
1 000 |
3 600,00 |
|
5 |
511 |
1 880,48 |
08/07/2023 |
2 |
500 |
1 810,00 |
|
- |
- |
- |
08/08/2023 |
3 |
1 000 |
3 600,00 |
|
1 |
250 |
915,00 |
08/09/2023 |
1 |
250 |
885,00 |
|
2 |
500 |
1 800,00 |
08/10/2023 |
5 |
501 |
1 773,54 |
|
1 |
250 |
890,00 |
08/11/2023 |
10 |
1 249 |
4 309,05 |
|
7 |
1 137 |
3 990,87 |
08/14/2023 |
6 |
1 500 |
5 235,00 |
|
2 |
251 |
881,01 |
08/15/2023 |
12 |
1 750 |
6 002,50 |
|
- |
- |
- |
08/16/2023 |
- |
- |
- |
|
1 |
500 |
1 700,00 |
08/17/2023 |
10 |
501 |
1 673,34 |
|
4 |
251 |
843,36 |
08/18/2023 |
6 |
750 |
2 475,00 |
|
- |
- |
- |
08/21/2023 |
2 |
136 |
454,24 |
|
6 |
1 031 |
3 484,78 |
08/22/2023 |
4 |
314 |
1 058,18 |
|
4 |
969 |
3 304,29 |
08/23/2023 |
6 |
1 000 |
3 400,00 |
|
5 |
1 250 |
4 300,00 |
08/24/2023 |
5 |
1 000 |
3 360,00 |
|
1 |
1 |
3,46 |
|
Buy Side |
|
Sell Side |
|
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Total |
828 |
157 508 |
584 045,97 |
|
877 |
180 395 |
695 421,23 |
|
08/25/2023 |
6 |
1 238 |
4 060,64 |
|
- |
- |
- |
|
08/28/2023 |
2 |
36 |
116,64 |
|
1 |
500 |
1 665,00 |
|
08/29/2023 |
3 |
214 |
693,36 |
|
3 |
133 |
438,90 |
|
08/30/2023 |
7 |
1 000 |
3 200,00 |
|
2 |
185 |
592,00 |
|
08/31/2023 |
- |
- |
- |
|
55 |
15 157 |
57 899,74 |
|
09/01/2023 |
1 |
250 |
835,00 |
|
8 |
2 000 |
7 620,00 |
|
09/04/2023 |
3 |
750 |
2 632,50 |
|
- |
- |
- |
|
09/05/2023 |
3 |
500 |
1 750,00 |
|
- |
- |
- |
|
09/06/2023 |
5 |
1 500 |
5 145,00 |
|
1 |
500 |
1 820,00 |
|
09/07/2023 |
5 |
1 250 |
4 187,50 |
|
- |
- |
- |
|
09/08/2023 |
1 |
1 |
3,40 |
|
3 |
251 |
853,40 |
|
09/11/2023 |
5 |
500 |
1 670,00 |
|
8 |
1 250 |
4 237,50 |
|
09/12/2023 |
6 |
1 651 |
5 514,34 |
|
- |
- |
- |
|
09/13/2023 |
- |
- |
- |
|
30 |
7 311 |
26 319,60 |
|
09/14/2023 |
- |
- |
- |
|
9 |
1 439 |
5 381,86 |
|
09/15/2023 |
1 |
500 |
1 850,00 |
|
7 |
750 |
2 842,50 |
|
09/18/2023 |
10 |
2 500 |
9 275,00 |
|
6 |
1 500 |
5 610,00 |
|
09/19/2023 |
13 |
1 823 |
6 672,18 |
|
6 |
1 100 |
4 070,00 |
|
09/20/2023 |
3 |
777 |
2 804,97 |
|
7 |
1 000 |
3 690,00 |
|
09/21/2023 |
14 |
2 250 |
9 135,00 |
|
37 |
9 250 |
39 775,00 |
|
09/22/2023 |
1 |
500 |
1 945,00 |
|
13 |
2 500 |
10 300,00 |
|
09/25/2023 |
4 |
1 000 |
4 300,00 |
|
8 |
2 750 |
12 072,50 |
|
09/26/2023 |
17 |
3 500 |
14 980,00 |
|
18 |
4 150 |
18 218,50 |
|
09/27/2023 |
14 |
3 000 |
12 510,00 |
|
6 |
1 011 |
4 377,63 |
|
09/28/2023 |
25 |
4 750 |
18 715,00 |
|
14 |
3 871 |
15 522,71 |
|
09/29/2023 |
2 |
500 |
2 050,00 |
|
17 |
3 369 |
13 880,28 |
|
10/02/2023 |
6 |
1 500 |
6 195,00 |
|
10 |
2 000 |
8 480,00 |
|
10/03/2023 |
20 |
2 175 |
8 743,50 |
|
1 |
250 |
1 015,00 |
|
10/04/2023 |
8 |
1 475 |
5 826,25 |
|
6 |
1 000 |
3 990,00 |
|
10/05/2023 |
10 |
2 750 |
10 725,00 |
|
7 |
750 |
2 970,00 |
|
10/06/2023 |
6 |
1 368 |
5 307,84 |
|
11 |
2 000 |
7 880,00 |
|
10/09/2023 |
13 |
2 882 |
10 922,78 |
|
4 |
751 |
2 876,33 |
|
10/10/2023 |
8 |
1 750 |
6 422,50 |
|
- |
- |
- |
|
10/11/2023 |
5 |
1 000 |
3 600,00 |
|
3 |
501 |
1 808,61 |
|
10/12/2023 |
5 |
1 001 |
3 693,69 |
|
11 |
1 951 |
7 277,23 |
|
10/13/2023 |
- |
- |
- |
|
6 |
750 |
2 842,50 |
|
10/16/2023 |
7 |
1 194 |
4 405,86 |
|
- |
- |
- |
|
10/17/2023 |
17 |
3 256 |
11 428,56 |
|
4 |
850 |
3 009,00 |
|
|
Buy Side |
|
Sell Side |
|
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Total |
828 |
157 508 |
584 045,97 |
|
877 |
180 395 |
695 421,23 |
|
10/18/2023 |
8 |
1 500 |
5 205,00 |
|
- |
- |
- |
|
10/19/2023 |
14 |
2 750 |
9 350,00 |
|
3 |
510 |
1 749,30 |
|
10/20/2023 |
19 |
1 500 |
5 055,00 |
|
- |
- |
- |
|
10/23/2023 |
11 |
2 750 |
8 800,00 |
|
19 |
2 500 |
8 175,00 |
|
10/24/2023 |
- |
- |
- |
|
16 |
2 640 |
9 108,00 |
|
10/25/2023 |
7 |
2 000 |
6 880,00 |
|
1 |
1 |
3,44 |
|
10/26/2023 |
6 |
750 |
2 527,50 |
|
8 |
1 749 |
5 981,58 |
|
10/27/2023 |
5 |
279 |
976,50 |
|
7 |
1 251 |
4 378,50 |
|
10/30/2023 |
2 |
379 |
1 334,08 |
|
8 |
1 849 |
6 582,44 |
|
10/31/2023 |
8 |
1 000 |
3 600,00 |
|
4 |
500 |
1 805,00 |
|
11/01/2023 |
6 |
1 356 |
4 718,88 |
|
1 |
1 |
3,59 |
|
11/02/2023 |
3 |
500 |
1 750,00 |
|
2 |
500 |
1 820,00 |
|
11/03/2023 |
- |
- |
- |
|
2 |
250 |
915,00 |
|
11/06/2023 |
7 |
1 750 |
6 387,50 |
|
7 |
1 982 |
7 472,14 |
|
11/07/2023 |
10 |
2 250 |
8 302,50 |
|
21 |
4 017 |
15 385,11 |
|
11/08/2023 |
7 |
1 250 |
4 525,00 |
|
6 |
622 |
2 282,74 |
|
11/09/2023 |
4 |
1 250 |
4 437,50 |
|
1 |
1 |
3,66 |
|
11/10/2023 |
19 |
2 750 |
9 432,50 |
|
1 |
250 |
860,00 |
|
11/13/2023 |
11 |
1 512 |
5 201,28 |
|
6 |
1 000 |
3 460,00 |
|
11/14/2023 |
3 |
988 |
3 408,60 |
|
10 |
1 999 |
7 076,46 |
|
11/15/2023 |
8 |
1 956 |
6 826,44 |
|
5 |
750 |
2 632,50 |
|
11/16/2023 |
9 |
1 744 |
6 016,80 |
|
5 |
1 500 |
5 250,00 |
|
11/17/2023 |
- |
- |
- |
|
3 |
750 |
2 692,50 |
|
11/20/2023 |
10 |
1 000 |
3 640,00 |
|
16 |
3 678 |
13 608,60 |
|
11/21/2023 |
9 |
2 000 |
7 320,00 |
|
6 |
1 000 |
3 690,00 |
|
11/22/2023 |
3 |
500 |
1 835,00 |
|
13 |
2 127 |
7 912,44 |
|
11/23/2023 |
8 |
1 633 |
6 009,44 |
|
5 |
1 473 |
5 567,94 |
|
11/24/2023 |
4 |
617 |
2 282,90 |
|
1 |
250 |
930,00 |
|
11/27/2023 |
2 |
1 000 |
3 800,00 |
|
16 |
5 500 |
21 450,00 |
|
11/28/2023 |
5 |
2 000 |
7 840,00 |
|
3 |
1 500 |
5 955,00 |
|
11/29/2023 |
6 |
1 022 |
3 955,14 |
|
7 |
2 500 |
9 775,00 |
|
11/30/2023 |
26 |
4 478 |
17 016,40 |
|
- |
- |
- |
|
12/01/2023 |
5 |
1 501 |
5 643,76 |
|
9 |
2 501 |
9 553,82 |
|
12/04/2023 |
- |
- |
- |
|
5 |
1 500 |
5 925,00 |
|
12/05/2023 |
6 |
2 000 |
8 180,00 |
|
21 |
4 501 |
18 499,11 |
|
12/06/2023 |
2 |
500 |
2 050,00 |
|
13 |
2 999 |
12 475,84 |
|
12/07/2023 |
- |
- |
- |
|
10 |
2 500 |
10 500,00 |
|
12/08/2023 |
4 |
1 000 |
4 200,00 |
|
1 |
500 |
2 105,00 |
|
|
Buy Side |
|
Sell Side |
|
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Number ofexecutions |
Number ofshares |
Traded volume in EUR |
|
Total |
828 |
157 508 |
584 045,97 |
|
877 |
180 395 |
695 421,23 |
|
12/11/2023 |
6 |
1 000 |
4 170,00 |
|
5 |
1 252 |
5 283,44 |
|
12/12/2023 |
28 |
5 500 |
21 835,00 |
|
11 |
1 001 |
4 014,01 |
|
12/13/2023 |
5 |
1 500 |
5 835,00 |
|
6 |
249 |
986,04 |
|
12/14/2023 |
2 |
501 |
1 953,90 |
|
7 |
1 000 |
3 910,00 |
|
12/15/2023 |
7 |
1 499 |
5 756,16 |
|
3 |
762 |
2 964,18 |
|
12/18/2023 |
- |
- |
- |
|
3 |
488 |
1 903,20 |
|
12/19/2023 |
6 |
501 |
1 963,92 |
|
1 |
250 |
982,50 |
|
12/20/2023 |
1 |
1 |
3,94 |
|
18 |
3 949 |
16 151,41 |
|
12/21/2023 |
19 |
3 050 |
12 291,50 |
|
17 |
1 750 |
7 157,50 |
|
12/22/2023 |
7 |
900 |
3 681,00 |
|
16 |
3 250 |
13 617,50 |
|
12/27/2023 |
6 |
1 100 |
4 631,00 |
|
14 |
3 400 |
14 484,00 |
|
12/28/2023 |
8 |
2 150 |
8 965,50 |
|
7 |
1 750 |
7 420,00 |
|
12/29/2023 |
7 |
1 537 |
6 301,70 |
|
4 |
450 |
1 845,00 |
|
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH,
mucopolysaccharidoses (MPS) and other diseases with significant
unmet medical needs. The Company benefits from a strong expertise
and experience in the domain of compounds targeting nuclear
receptors, transcription factors and epigenetic modulation.
Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other
development opportunities to add to its pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting an oncology development candidate for its
Hippo signaling pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
Inventiva Pascaline Clerc, PhD EVP, Strategy and
Corporate Affairs media@inventivapharma.com +1 202 499
89375 |
Brunswick Group Tristan Roquet Montegon / Aude
Lepreux / Matthieu Benoist Media relations
inventiva@brunswickgroup.com +33 1 53 96 83 83 |
Westwicke, an ICR Company Patricia L. Bank
Investor relations patti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, expectations with respect to clinical
trials, regulatory plans, including the ongoing NATiV3 Phase III
clinical trial with lanifibranor in patients with NASH and
anticipated results and timing thereof, the potential development
of and regulatory pathway for odiparcil, the potential therapeutic
benefits of Inventiva’s product candidates, Inventiva’s future
activities, expectations, plans, growth and prospects, Inventiva’s
ability to exercise its rights under the Finance Contract and
warrant agreement with the EIB, including its call right and right
of first refusal, expectations with respect to EIB’s rights under
the agreements and EIB’s potential exercise of warrants, the
expected use of proceeds from the EIB facility, Inventiva's ability
to repay the EIB loans and the timing thereof, and the sufficiency
of Inventiva’s cash resources and cash runway. Certain of these
statements, forecasts and estimates can be recognized by the use of
words such as, without limitation, “believes”, “anticipates”,
“expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”,
“would”, “could”, “might”, “should”, “designed”, “hopefully”,
“target”, “potential”, “possible,” “aim”, and “continue” and
similar expressions. Such statements are not historical facts but
rather are statements of future expectations and other
forward-looking statements that are based on management's beliefs.
These statements reflect such views and assumptions prevailing as
of the date of the statements and involve known and unknown risks
and uncertainties that could cause future results, performance or
future events to differ materially from those expressed or implied
in such statements. Actual events are difficult to predict and may
depend upon factors that are beyond Inventiva's control. There can
be no guarantees with respect to pipeline product candidates that
the clinical trial results will be available on their anticipated
timeline, that future clinical trials will be initiated as
anticipated, that product candidates will receive the necessary
regulatory approvals, or that any of the anticipated milestones by
Inventiva or its partners will be reached on their expected
timeline, or at all. Future results may turn out to be materially
different from the anticipated future results, performance or
achievements expressed or implied by such statements, forecasts and
estimates, due to a number of factors, including that Inventiva is
a clinical-stage company with no approved products and no
historical product revenues, Inventiva has incurred significant
losses since inception, Inventiva has a limited operating history
and has never generated any revenue from product sales, Inventiva
will require additional capital to finance its operations, in the
absence of which, Inventiva may be required to significantly
curtail, delay or discontinue one or more of its research or
development programs or be unable to expand its operations or
otherwise capitalize on its business opportunities and may be
unable to continue as a going concern, Inventiva's future success
is dependent on the successful clinical development, regulatory
approval and subsequent commercialization of current and any future
product candidates, preclinical studies or earlier clinical trials
are not necessarily predictive of future results and the results of
Inventiva's and its partners’ clinical trials may not support
Inventiva's and its partners’ product candidate claims, Inventiva’s
expectations with respect to the changes to the clinical
development plan for lanifibranor for the treatment of NASH may not
be realized and may not support the approval of a New Drug
Application, Inventiva and its partners may encounter substantial
delays in their clinical trials or fail to demonstrate safety and
efficacy to the satisfaction of applicable regulatory authorities,
the ability of Inventiva and its partners to recruit and retain
patients in clinical studies, enrolment and retention of patients
in clinical trials is an expensive and time-consuming process and
could be made more difficult or rendered impossible by multiple
factors outside Inventiva's and its partners’ control, Inventiva's
product candidates may cause adverse drug reactions or have other
properties that could delay or prevent their regulatory approval,
or limit their commercial potential, Inventiva faces substantial
competition and Inventiva’s and its partners' business, and
preclinical studies and clinical development programs and
timelines, its financial condition and results of operations could
be materially and adversely affected by geopolitical events, such
as the conflict between Russia and Ukraine and related sanctions,
impacts and potential impacts on the initiation, enrolment and
completion of Inventiva’s and its partners’ clinical trials on
anticipated timelines and the state of war between Israel and Hamas
and the related risk of a larger conflict, health epidemics, and
macroeconomic conditions, including global inflation, rising
interest rates, uncertain financial markets and disruptions in
banking systems. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as
of the date of this press release. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2022 filed with the
Autorité des Marchés Financiers on March 30, 2023 as amended on
August 31, 2023, the Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the Securities and Exchange Commission
on March 30, 2023, and the Half-Year Report for the six months
ended June 30, 2023 on Form 6-K filed with the SEC on October 3,
2023, for other risks and uncertainties affecting Inventiva,
including those described from time to time under the caption “Risk
Factors”. Other risks and uncertainties of which Inventiva is not
currently aware may also affect its forward-looking statements and
may cause actual results and the timing of events to differ
materially from those anticipated. All information in this press
release is as of the date of the release. Except as required by
law, Inventiva has no intention and is under no obligation to
update or review the forward-looking statements referred to above.
Consequently, Inventiva accepts no liability for any consequences
arising from the use of any of the above statement.
- Inventiva - PR - Liquidity contract - H2 23 - EN - 01 24
2024
Inventiva (EU:IVA)
Historical Stock Chart
From May 2024 to Jun 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2023 to Jun 2024